Research Article: Adjuvant Lenvatinib Plus PD- Antibody for Hepatocellular Carcinoma with High Recurrence Risks After Hepatectomy: A Retrospective Landmark Analysis
Introduction:
Hepatocellular carcinoma (HCC) is the sixth most widespread malignant tumor and the fourth leading cause of cancer-related death worldwide. Hepatectomy has long been the backbone of curative therapies for HCC, with a -year survival of –%. , However, the five-year recurrence rate of up to % is a major obstacle to survival.
Read more